<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03550001</url>
  </required_header>
  <id_info>
    <org_study_id>2017-PKUPH077</org_study_id>
    <nct_id>NCT03550001</nct_id>
  </id_info>
  <brief_title>Carbon Nanoparticles as Lymph Node Tracer in Rectal Cancer After Neoadjuvant Radiochemotherapy</brief_title>
  <acronym>CALOR-NAT</acronym>
  <official_title>Prospective Randomized Clinical Trial of Carbon Nanoparticles as Lymph Node Tracer in Rectal Cancer After Neoadjuvant Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>YE Yingjiang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether injection of carbon nanoparticle as a lymph
      node tracer before neoadjuvant radiochemotherapy in rectal cancer can increase lymph node
      yield after surgery compared which do not inject.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the randomized controlled, multi-centers，and open-labeled study. The lymph node yield
      was significantly decreased in rectal cancer after neoadjuvant radiochemotherapy (NAT), hard
      for pathologists to detect, and is difficult to meet the guideline that minimun of 12 lymph
      nodes should be retrived after surgery in colorectal cancer. Carbon nanoparticle (CNP) is a
      specific lymph node tracer, which only dyeing the lymph node, and can keep the lymph node in
      dyeing state in at least half year. The inverstigator attempted to compare the amount of
      lymph node yield after surgery in locally advanced rectal caner between injection CNP before
      NAT and no injection CNP before NAT. In this study, the participants with clinical TNM stage
      T3+ or N+ will be recruited. The participants will be randomized (1:1 ratio) to a control and
      intervention arm. The participants in the control arm will not receive injection of any kind
      lymph node tracers. The participants in the intervention arm will receive injection of CNP
      before NAT. And the specimen would be evaluated by the pathologist.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>lymph node yield</measure>
    <time_frame>up to 30days after total mesorectal excision</time_frame>
    <description>Amount of lymph node yield, dyeing lymph node, positive lymph node and the dyeing positive lymph node</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact on surgical operations</measure>
    <time_frame>Time of surgery</time_frame>
    <description>The impact of CNP to operational level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of surgery</measure>
    <time_frame>Time of surgery</time_frame>
    <description>Quality of surgery determined using the mesorectal grading system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery morbidity</measure>
    <time_frame>30 days and 12-months</time_frame>
    <description>Surgical morbidity reported according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5-years</time_frame>
    <description>Overall Survival is defined as the time from the date of surgery to the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5-years</time_frame>
    <description>Disease Free Survival is defined as the time from the date of surgery to the date of the local recurrence, and/or distant disease, or tumor-related death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>5-years</time_frame>
    <description>Local recurrence rate is defined as the time from the date of surgery to the date of the local recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Injection CNP before NAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject carbon nanoparticle as a lymph node tracer before the patient receive neoadjuvant therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No injection</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Do not inject carbon nanoparticle during the treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Injection CNP before NAT</intervention_name>
    <description>Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy</description>
    <arm_group_label>Injection CNP before NAT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-75 years old;

          2. Histologically confirmed adenocarcinoma;

          3. The rectal adenocarcinoma 0-12cm from the anal margin;

          4. Clinical TNM stage: T3+ or N+;

          5. Untreated patients (who have not received treatment including radiotherapy,
             chemotherapy, and surgery);

          6. Good liver and kidney function, without contraindications for radiotherapy,
             chemotherapy or surgery;

          7. Able and willing to give informed consent to participate;

        Exclusion Criteria:

          1. Malignant tumor history or other malignant tumors;

          2. Emergency operations such as intestinal obstruction, perforation and hemorrhage;

          3. Pregnant or lactating women;

          4. History of severe mental illness;

          5. Contraindications for radiotherapy, chemotherapy and surgery;

          6. Conditions that the researcher thinks it is not suitable for selection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingjiang Ye, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingjiang Ye, MD,PhD</last_name>
    <phone>8610-88326608</phone>
    <email>yeyingjiang@pkuph.edu.cn, yjye101@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhidong Gao, MD</last_name>
    <phone>8610-88326605</phone>
    <email>gaozhidong@pkuph.edu.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40. doi: 10.1093/annonc/mdx224. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv263. Ann Oncol. 2018 Oct;29 Suppl 4:iv263.</citation>
    <PMID>28881920</PMID>
  </reference>
  <reference>
    <citation>Mechera R, Schuster T, Rosenberg R, Speich B. Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis. Eur J Cancer. 2017 Feb;72:84-94. doi: 10.1016/j.ejca.2016.10.031. Epub 2016 Dec 24. Review.</citation>
    <PMID>28027520</PMID>
  </reference>
  <reference>
    <citation>Gurawalia J, Dev K, Nayak SP, Kurpad V, Pandey A. Less than 12 lymph nodes in the surgical specimen after neoadjuvant chemo-radiotherapy: an indicator of tumor regression in locally advanced rectal cancer? J Gastrointest Oncol. 2016 Dec;7(6):946-957. doi: 10.21037/jgo.2016.09.03.</citation>
    <PMID>28078118</PMID>
  </reference>
  <reference>
    <citation>Kim HJ, Jo JS, Lee SY, Kim CH, Kim YJ, Kim HR. Low Lymph Node Retrieval After Preoperative Chemoradiation for Rectal Cancer is Associated with Improved Prognosis in Patients with a Good Tumor Response. Ann Surg Oncol. 2015;22(6):2075-81. doi: 10.1245/s10434-014-4235-z. Epub 2014 Nov 14.</citation>
    <PMID>25395150</PMID>
  </reference>
  <reference>
    <citation>Xu Z, Berho ME, Becerra AZ, Aquina CT, Hensley BJ, Arsalanizadeh R, Noyes K, Monson JRT, Fleming FJ. Lymph node yield is an independent predictor of survival in rectal cancer regardless of receipt of neoadjuvant therapy. J Clin Pathol. 2017 Jul;70(7):584-592. doi: 10.1136/jclinpath-2016-203995. Epub 2016 Dec 8.</citation>
    <PMID>27932667</PMID>
  </reference>
  <reference>
    <citation>Lykke J, Jess P, Roikjaer O; Danish Colorectal Cancer Group. A minimum yield of twelve lymph nodes in rectal cancer remains valid in the era of neo-adjuvant treatment : results from a national cohort study. Int J Colorectal Dis. 2015 Mar;30(3):347-51. doi: 10.1007/s00384-015-2145-6. Epub 2015 Feb 5.</citation>
    <PMID>25652878</PMID>
  </reference>
  <reference>
    <citation>Lykke J, Jess P, Roikjaer O; Danish Colorectal Cancer Group. Increased Lymph Node Yield Is Associated With Improved Survival in Rectal Cancer Irrespective of Neoadjuvant Treatment: Results From a National Cohort Study. Dis Colon Rectum. 2015 Sep;58(9):823-30. doi: 10.1097/DCR.0000000000000429.</citation>
    <PMID>26252843</PMID>
  </reference>
  <reference>
    <citation>Bhangu A, Kiran RP, Brown G, Goldin R, Tekkis P. Establishing the optimum lymph node yield for diagnosis of stage III rectal cancer. Tech Coloproctol. 2014 Aug;18(8):709-17. doi: 10.1007/s10151-013-1114-8. Epub 2014 Feb 11.</citation>
    <PMID>24515286</PMID>
  </reference>
  <reference>
    <citation>Carvalho C, Glynne-Jones R. Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncol. 2017 Jun;18(6):e354-e363. doi: 10.1016/S1470-2045(17)30346-7. Review. Erratum in: Lancet Oncol. 2018 Mar;19(3):e137.</citation>
    <PMID>28593861</PMID>
  </reference>
  <reference>
    <citation>Horne J, Carr NJ, Bateman AC, Kandala N 2nd, Adams J, Silva S, Ryder I. A comparison of formalin and GEWF in fixation of colorectal carcinoma specimens: rates of lymph node retrieval and effect on TNM staging. J Clin Pathol. 2016 Jun;69(6):511-7. doi: 10.1136/jclinpath-2015-203281. Epub 2015 Nov 30.</citation>
    <PMID>26621110</PMID>
  </reference>
  <reference>
    <citation>Yegen G, Keskin M, Büyük M, Kunduz E, Balık E, Sağlam EK, Kapran Y, Asoğlu O, Güllüoğlu M. The effect of neoadjuvant therapy on the size, number, and distribution of mesorectal lymph nodes. Ann Diagn Pathol. 2016 Feb;20:29-35. doi: 10.1016/j.anndiagpath.2015.10.008. Epub 2015 Oct 29.</citation>
    <PMID>26706785</PMID>
  </reference>
  <reference>
    <citation>Münster M, Hanisch U, Tuffaha M, Kube R, Ptok H. Ex Vivo Intra-arterial Methylene Blue Injection in Rectal Cancer Specimens Increases the Lymph-Node Harvest, Especially After Preoperative Radiation. World J Surg. 2016 Feb;40(2):463-70. doi: 10.1007/s00268-015-3230-2.</citation>
    <PMID>26310202</PMID>
  </reference>
  <reference>
    <citation>Farinella E, Viganò L, Fava MC, Mineccia M, Bertolino F, Capussotti L. In vivo lymph node mapping and pattern of metastasis spread in locally advanced mid/low rectal cancer after neoadjuvant chemoradiotherapy. Int J Colorectal Dis. 2013 Nov;28(11):1523-9. doi: 10.1007/s00384-013-1727-4. Epub 2013 Jul 23.</citation>
    <PMID>23877264</PMID>
  </reference>
  <reference>
    <citation>Zhang XM, Liang JW, Wang Z, Kou JT, Zhou ZX. Effect of preoperative injection of carbon nanoparticle suspension on the outcomes of selected patients with mid-low rectal cancer. Chin J Cancer. 2016 Apr 4;35:33. doi: 10.1186/s40880-016-0097-z.</citation>
    <PMID>27044280</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Deng H, Chen H, Liu H, Xue Q, Yan J, Li G. Preoperative Submucosal Injection of Carbon Nanoparticles Improves Lymph Node Staging Accuracy in Rectal Cancer after Neoadjuvant Chemoradiotherapy. J Am Coll Surg. 2015 Nov;221(5):923-30. doi: 10.1016/j.jamcollsurg.2015.07.455. Epub 2015 Aug 20.</citation>
    <PMID>26362137</PMID>
  </reference>
  <reference>
    <citation>Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2.</citation>
    <PMID>19638912</PMID>
  </reference>
  <reference>
    <citation>Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994 Jun 1;73(11):2680-6.</citation>
    <PMID>8194005</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>YE Yingjiang</investigator_full_name>
    <investigator_title>Professor of Surgery, Director of Department of Gastroenterological Surgery</investigator_title>
  </responsible_party>
  <keyword>locally advanced rectal cancer</keyword>
  <keyword>lymph node yeild</keyword>
  <keyword>lymph node tracer</keyword>
  <keyword>stage shift</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We need to discuss with other centers, then decide whether to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

